News: Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

74.70CHF
17 Apr 2014
Price Change (% chg)

CHF0.35 (+0.47%)
Prev Close
CHF74.35
Open
CHF74.40
Day's High
CHF74.70
Day's Low
CHF73.75
Volume
4,874,616
Avg. Vol
5,826,423
52-wk High
CHF75.75
52-wk Low
CHF63.20

Search Stocks
Select another date:

Thu, Apr 10 2014

Photo

Stockpiles of Roche Tamiflu drug are waste of money, review finds

LONDON - Researchers who have fought for years to get full data on Roche's flu medicine Tamiflu said on Thursday that governments who stockpile it are wasting billions of dollars on a drug whose effectiveness is in doubt. | Video

UPDATE 2-French antitrust watchdog probes Roche and Novartis over eye drug

* French regulator probes Swiss firms over wet AMD treatments

Roche says did not collude with Novartis to restrict competition

ZURICH - Swiss drugmaker Roche said on Thursday that it had not colluded with Novartis to restrict competition for eye disease treatments.

Roche says did not collude with Novartis to restrict competition

ZURICH, April 10 - Swiss drugmaker Roche said on Thursday that it had not colluded with Novartis to restrict competition for eye disease treatments.

French antitrust body probes Roche, Novartis over eye treatment

PARIS/ZURICH, April 10 - France's competition authority is investigating drugmakers Roche and Novartis on suspicion they were involved in anti-competitive practices in respect of eye disease treatment, the companies said on Thursday.

Novartis names new heads for Alcon and Sandoz divisions

ZURICH, April 9 - Swiss drugmaker Novartis has appointed new heads of its eyecare business Alcon and generics division Sandoz, the group's second and third largest businesses after pharmaceuticals.

Novartis' meningitis B vaccine wins breakthrough therapy status in U.S.

ZURICH - Novartis said U.S. health regulators have granted the Swiss drugmaker's meningitis B vaccine Bexsero breakthrough therapy status.

Novartis' meningitis B vaccine wins breakthrough therapy status in U.S.

ZURICH, April 7 - Novartis said U.S. health regulators have granted the Swiss drugmaker's meningitis B vaccine Bexsero breakthrough therapy status.

Novartis replaces top management in Japan after probe on clinical trials

TOKYO - Novartis AG replaced the top managers at its Japanese unit on Thursday after a third-party probe found employees had acted questionably in clinical trials on a leukaemia treatment.

Novartis replaces top management in Japan after probe on clinical trials

TOKYO, April 3 - Novartis AG replaced the top managers at its Japanese unit on Thursday after a third-party probe found employees had acted questionably in clinical trials on a leukaemia treatment.

Select another date:
Search Stocks